Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients.

Soysal, Savas D; Ng, Charlotte K. Y.; Costa, Luigi; Weber, Walter P; Paradiso, Viola; Piscuoglio, Salvatore; Muenst, Simone (2019). Genetic Alterations in Benign Breast Biopsies of Subsequent Breast Cancer Patients. Frontiers in medicine, 6, p. 166. Frontiers 10.3389/fmed.2019.00166

[img]
Preview
Text
fmed-06-00166.pdf - Published Version
Available under License Creative Commons: Attribution (CC-BY).

Download (282kB) | Preview

Background: Fibrocystic changes are associated with an increased risk of breast cancer. Genetic alterations have been found in fibrocystic changes with or without epithelial changes, suggesting that critical oncogenic events are occurring at an early stage. Methods: We investigated a unique collective of 17 breast cancer patients who, prior to the diagnosis of invasive breast cancer, underwent open surgical biopsy showing fibrocystic changes of the breast. The time span between biopsy for fibrocystic changes and invasive carcinoma ranged from 1 to 11 years (average 5.3 years). Ten (58.8%) of the patients had an ipsilateral invasive carcinoma, and 7 (41.2%) of the patients developed an invasive carcinoma of the contralateral breast. Massive parallel sequencing targeting genes frequently mutated in breast cancer was performed on the fibrocystic breast tissue as well as the ensuing cancer tissue. Results: In 9 cases, somatic mutations were found in the tumor tissue, the most prevalent being PIK3CA mutations (n = 4), followed by TP53 mutations (n = 2). None of these mutations were present in the previously removed mastopathy tissue. In one of the cases, an ERBB3 E928G mutation was present in the mastopathy as well as in the tumor tissue, with the variant allele frequency in the mastopathy being <0.1%. In two patients, we found two mutations (MAP3K1 L380fs and PIK3CA I391M, respectively) present in the mastopathy as well as in the subsequent breast cancer. These two mutations, however, could also be due to fixation artifacts. Conclusion: Since no significant somatic mutations in the fibrocystic breast tissue, and only doubtful shared mutations between benign and associated cancer tissue were detected, it remains unclear why women with fibrocystic breast disease have a statistically significant increased risk of breast cancer. Further analyses, maybe on the level of gene expression, could help to clarify the role of these benign alterations in the development of breast cancer and help to identify women at greater risk of developing subsequent invasive cancer.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR)

UniBE Contributor:

Ng, Kiu Yan Charlotte

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2296-858X

Publisher:

Frontiers

Language:

English

Submitter:

Marla Rittiner

Date Deposited:

12 Dec 2019 12:25

Last Modified:

15 Dec 2019 02:45

Publisher DOI:

10.3389/fmed.2019.00166

PubMed ID:

31396514

Uncontrolled Keywords:

breast cancer carcinogenesis fibrocystic mastopathy genetic alteration somatic mutation

BORIS DOI:

10.7892/boris.136297

URI:

https://boris.unibe.ch/id/eprint/136297

Actions (login required)

Edit item Edit item
Provide Feedback